Treatment of pelvic osteosarcoma

Area of Science:

• Oncology
• Orthopedic Oncology
• Medical Research

Background:

• Pelvic osteosarcoma is a rare, aggressive bone cancer with a poor prognosis, primarily affecting young individuals.
• The study reviewed 26 cases of pelvic osteosarcoma diagnosed between June 1987 and the study's completion.
• A significant portion of patients (7/26) presented with lung metastases at initial diagnosis.

Purpose of the Study:

• To evaluate treatment strategies and outcomes for patients with pelvic osteosarcoma.
• To assess the efficacy of neoadjuvant chemotherapy, surgery, and radiotherapy in managing this rare malignancy.
• To identify factors influencing survival rates in pelvic osteosarcoma.

Main Methods:

• Retrospective analysis of 26 pelvic osteosarcoma patients (12 female, 14 male, median age 23).
• Treatment modalities included neoadjuvant chemotherapy (methotrexate, leucovorin, cisplatin, epidoxorubicin), surgery (hemipelvectomy), and radiotherapy with cisplatin.
• All patients received a combination of epidoxorubicin, ifosfamide, methotrexate, cisplatin, and etoposide.

Main Results:

• Neoadjuvant chemotherapy yielded 8 partial responses (PR), 9 stable disease (SD), and 1 progressive disease (PD).
• Surgical outcomes: 2 of 4 patients survived disease-free post-hemipelvectomy; 2 died within 18 months.
• Radiotherapy outcomes: 5 of 14 patients survived with a median of 20 months; 9 died with a median survival of 18 months.

Conclusions:

• Pelvic osteosarcoma currently has a limited cure rate.
• Combined treatment approaches show potential but require further optimization.
• Earlier diagnosis and improved multimodal therapeutic strategies are crucial for enhancing survival in pelvic osteosarcoma patients.